>
America Is Building Its First New Oil Refinery in 50 Years -- And It's Made for American Oil
Floating Energy Assets Explained
What if Iran's next move against Washington is not a missile launch, but a convoy of oil tankers
Dubai Just Finished the World's First Permanent Air Taxi Route: Airport to the Marina in Under 1
Doroni Aerospace Raises More than $60m for H1?X Development
After 13 Years Battling Cancer, a 61-Year-Old Brazilian Man Achieved Complete Remission...
Extraterrestrial habitats may rise via Legos of laser-fused moon dust
Battery-only 19-seater puts China in the electric airliner race
Dream Chaser space plane gets landing approval for debut mission in 2027
SpaceX Just Caught Starship on Its FIRST Attempt!
Solid-State Cells Can Make The U.S. Competitive In Batteries Again: CEO
Jetson ONE personal eVTOL pod is about to go full sky patrol
America's INSANE BREAKTHROUGH Could Replace Septic Tanks Forever

In 2013, GlaxoSmithKline shutdown Sirtris (David Sinclair's company) about five years after spending $720 million to buy Sirtris.
David A. Sinclair, Ph.D., A.O. is a Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School. Dr. Sinclair is co-founder of several biotechnology companies (Sirtris, Ovascience, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others. He is also co-founder and co-chief editor of the journal Aging.
Life Biosciences was co-founded in 2017 by David A. Sinclair, PhD, AO, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, an investment professional who developed its innovative company structure.